Niki BioSolutions, Inc. (APM) Form S-3 — Aug 27, 2026
Niki BioSolutions filed a Form S-3 shelf registration (pre-effective Amendment No. 1) registering up to $75,000,000 of common stock, preferred stock, debt securities, warrants, subscription rights, and units for sale from time to time. The filing replaces the company's prior Form F-3 shelf because Niki no longer qualifies as a foreign private issuer following its domestication, and no shares were sold under the prior F-3. Niki BioSolutions is the renamed Aptorum Group, which moved from the Cayman Islands to Delaware and closed its merger with DiamiR Biosciences on July 20, 2026, the same day a 1-for-10 reverse stock split took effect.
Key figures
- Eps
- -$1.6 (six months ended June 30, 2026, adjusted for 1-for-10 reverse stock split)
- Net Income
- -$1,326,004 (net loss available to common shareholders, six months ended June 30, 2026)
- Gross Proceeds
- up to $75,000,000 (maximum aggregate shelf capacity; no securities sold under prior F-3)
- Shares Outstanding
- 2938625
- Public Float Shares
- 2723024
- Reverse Split Ratio
- 1-for-10 (effective July 20, 2026)
- Public Float Value Usd
- 20422681
- Closing Price Aug25 2026
- 7.91
- Authorized Capital Shares
- 160000000
- Warrant Exercise Price Usd
- 0.01
- Outstanding Warrant Shares
- 56625
- Series APreferred Shares Outstanding
- 179693
Price after filing
Close on the filing date to close N calendar days later (from $7.54). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.